The actress who is succeeding with the fifth season of Emily in Paris has transformed her personal struggle with eating ...

Those on Lilly’s pill outperformed the placebo on weight loss maintenance. Former Wegovy users on the pill regained just 2 ...

Patients on Eli Lilly’s next-generation obesity shot lost nearly 30% of their body weight on average in a trial that tracked them for a little more than a year—a result that’s far better than the most ...

Eli Lilly LLY1.84%increase; green up pointing triangle said its next generation weight-loss drug retatrutide helped people lose up to 28.7% of their body weight after more than a year of treatment, ...

Eli Lilly's experimental weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in a phase three trial involving patients with obesity and knee osteoarthritis. The ...

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in a late-stage trial. The company said the drug delivered weight loss of up ...

Kenneth Custer is the president of Lilly Cardiometabolic Health. "Eli Lilly Reports Positive Results From Study of Weight Loss Drug for Patients with Osteoarthritis ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug. By Gina Kolata Gina Kolata has ...

Eli Lilly’s experimental weight-loss drug retatrutide led to an average weight reduction of up to 28.7%—more than 71 pounds—in adults with obesity or overweight and knee osteoarthritis. Participants ...

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar” for future obesity drug competitors, one analyst wrote. With the latest ...